Ixazomib
Ixazomib (MLN2238) is a selective, potent, and reversible proteasome inhibitor, which inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an IC50 of 3.4 nM (Ki of 0.93 nM) .
Product Specifications
CAS Number
1072833-77-2
Product Name Alternative
MLN2238
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; Proteasome
Type
Reference compound
Related Pathways
Autophagy; Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/MLN2238.html
Purity
99.85
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
OB([C@@H](NC(CNC(C1=CC(Cl)=CC=C1Cl)=O)=O)CC(C)C)O
Molecular Formula
C14H19BCl2N2O4
Molecular Weight
361.03
Precautions
H302, H315, H319, H335
References & Citations
[1]Friedman JR, et al. Anticancer Activity of Natural and Synthetic Capsaicin Analogs. J Pharmacol Exp Ther. 2018 Mar;364 (3) :462-473.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Adenylosuccinate Lyase (ADSL) (NM_001123378) Human Over-expression Lysate
CD31 / PECAM-1 (Endothelial Cell Marker) (PECAM1/3527), 0.2mg/mL
1-Bromo-2,4-dinitro-benzene-1,2,3,4,5,6-13C6
